Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 229-234

  Watari, Hidemichi ^a   Xiong, Ying ^a   Hassan, Mohamed K ^a   Sakuragi, Noriaki ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyr61; Endometrial carcinoma; Immunohistochemistry; Prognostic factor; Survival

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE RICH PROTEIN 61; MOLECULAR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NEPHROBLASTOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TISSUE SECTION; WESTERN BLOTTING;

CARCINOMA, ENDOMETRIOID; CYSTEINE-RICH PROTEIN 61; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 57649093432     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.09.039     Document Type: Article

References (20)

1. Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett. 327 (1993) 125-130
2. Planque N., and Peral B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int. 3 (2003) 15
3. Brigstock D.R. The CCN family: a new stimulus package. J. Endocrinol. 178 (2003) 169-175
4. Brigstock D.R. Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis 5 (2002) 153-165
5. Xie D., Nakachi K., Wang H., Elashoff R., and Koeffler H.P. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res. 61 (2001) 8917-8923 15
6. Xie D., Miller C.W., O'kelly J., Nakachi K., Sakashita A., Said J.W., et al. Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J. Biol. Chem. 276 (2001) 14187-14194
7. Babic A.M., Kireeva M.L., Kolesnilova T.V., and Lau L.F. Cyr61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumour growth. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6355-6360
8. Tong X., Xie D., O'kelly J Miller C.W., Muller-Tidow C., and Koeffler H.P. Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer. J. Biol. Chem. 276 (2001) 47709-47714
9. Tong X., O'kelly J., Xie D., Mori A., Lemp N., McKenna R., et al. Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway. Oncogene 23 (2004) 4847-4855
10. Pilarsky C.P., Schimidt U., Eissrich C., Stade J., Froschermaier S.E., Haase M., et al. Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. Prostate 36 (1998) 85-91
11. Wasenius V.M., Hemmer S., Kettunen E., Knuutila S., Franssila K., and Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin. Cancer Res. 9 (2003) 68-75
12. Chien W., Kumagai T., Miller C.W., Desmond J.C., Frank J.M., Said J.W., et al. Cyr61 suppresses growth of human endometrial cancer cells. J. Biol. Chem. 279 (2004) 53087-53096
13. MacLaughlan S.D., Polomino W.A., Mo B., Lewis T.D., Lininger R.A., and Lessey B.A. Endometrial expression of Cyr61. A marker of estrogenic activity in normal and abnormal endometrium. Obstet. Gynecol. 110 (2007) 146-154
14. Watari H., Todo Y., Takeda M., Ebina Y., Yamamoto R., and Sakuragi N. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer. Gynecol. Oncol. 96 (2005) 651-657
15. Xie D., Yin D., Wang H.J., Liu G.T., Elashoff R., Black K., et al. Levels of expression of Cyr61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin. Cancer Res. 10 (2004) 2072-2081
16. Singh M., Smith H.O., Leslie K.K., Qualls C.R., Revankar C.M., Joste N.E., et al. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am. J. Obstet. Gynecol. 196 (2007) 386.e1-386.e9
17. Gery S., Xie D., Yin D., Gabra H., Miller C., Wang H., et al. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin. Cancer Res. 11 (2005) 7243-7254
18. Lin M.T., Chang C.C., Chen S.T., Chang H.L., Su J.L., Chau Y.P., et al. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7cells by a mechanism of NF-kB-dependent XIAP up-regulation. J. Biol. Chem. 279 (2004) 24015-24023
19. Bonetti A., Zaninelli M., Rodella S., Molino A., Sperotto L., Piubello O., et al. Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma. Breast Cancer Rfes. Treat. 38 (1996) 289-297
20. O'Reilly S.M., Camplejohn R.S., Rubens R.D., and Richards M.A. DNA flowcytometry and response to preoperative chemotherapy for primary breast cancer. Eur. J. Cancer 28 (1992) 681-683